Company Analysis AnaptysBio, Inc.
1. Summary
Advantages
- Price (14.21 $) is less than fair price (21.35 $)
Disadvantages
- Dividends (0%) are below the sector average (0.5473%).
- The stock's return over the last year (-38.64%) is lower than the sector average (-31.05%).
- Current debt level 3.94% has increased over 5 years from 0.5055%.
- The company's current efficiency (ROE=-185.71%) is lower than the sector average (ROE=9.61%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| AnaptysBio, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -7.1% | -22.6% | -2.3% |
| 90 days | -59.1% | -35.5% | 3.7% |
| 1 year | -38.6% | -31% | 27.2% |
ANAB vs Sector: AnaptysBio, Inc. has significantly underperformed the "Healthcare" sector by -7.59% over the past year.
ANAB vs Market: AnaptysBio, Inc. has significantly underperformed the market by -65.84% over the past year.
Stable price: ANAB is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: ANAB with weekly volatility of -0.7432% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (14.21 $) is lower than the fair price (21.35 $).
Price significantly below the fair price: The current price (14.21 $) is 50.2% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (101.39) is higher than that of the sector as a whole (48.72).
P/E vs Market: The company's P/E (101.39) is higher than that of the market as a whole (49.05).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (6.34) is higher than that of the sector as a whole (4.82).
P/BV vs Market: The company's P/BV (6.34) is higher than that of the market as a whole (3.18).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (32.55) is lower than that of the sector as a whole (33.75).
P/S vs Market: The company's P/S indicator (32.55) is higher than that of the market as a whole (10.24).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-3.98) is higher than that of the sector as a whole (-22.17).
EV/Ebitda vs Market: The company's EV/Ebitda (-3.98) is lower than that of the market as a whole (28.35).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 184.52% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (184.52%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (123.79%).
5.4. ROE
ROE vs Sector: The company's ROE (-185.71%) is lower than that of the sector as a whole (9.61%).
ROE vs Market: The company's ROE (-185.71%) is lower than that of the market as a whole (10.67%).
5.5. ROA
ROA vs Sector: The company's ROA (-36.17%) is lower than that of the sector as a whole (0.3443%).
ROA vs Market: The company's ROA (-36.17%) is lower than that of the market as a whole (6.44%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-18.65%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (-18.65%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5473%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 02.01.2025 | EcoR1 Capital, LLC Director |
Purchase | 12.95 | 86 066 | 6 646 |
| 31.12.2024 | EcoR1 Capital, LLC Director |
Purchase | 12.93 | 171 555 | 13 268 |
| 30.12.2024 | EcoR1 Capital, LLC Director |
Purchase | 12.92 | 842 177 | 65 184 |
| 16.02.2024 | LOUMEAU ERIC J CHIEF LEGAL OFFICER |
Sale | 25 | 125 000 | 5 000 |
| 16.02.2024 | LOUMEAU ERIC J CHIEF LEGAL OFFICER |
Purchase | 14.02 | 70 100 | 5 000 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
